Advisors Asset Management’s Blueprint Medicines BPMC Stock Holding History

Advisors Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-5,453	Closed	-$699K	–	1462
2025 Q2	$699K	Sell	5,453 -100	-2%	-$10.4K	0.01%	877
2025 Q1	$491K	Sell	5,553 -333	-6%	-$32.5K	0.01%	932
2024 Q4	$513K	Buy	5,886 +832	+16%	+$76.2K	0.01%	922
2024 Q3	$467K	Buy	5,054 +756	+18%	+$75.1K	0.01%	949
2024 Q2	$463K	Buy	+4,298	New	+$430K	0.01%	921

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Advisors Asset Management's BPMC Position: Q3 2025 in Review

Advisors Asset Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 5,453 shares — an estimated $699K sold.

Advisors Asset Management first reported a position in BPMC in Q2 2024 and held it in 5 quarters. The position peaked at $699K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Advisors Asset Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Advisors Asset Management sold 5,453 Blueprint Medicines shares in Q3 2025, an estimated $699K.
Advisors Asset Management first reported a position in Blueprint Medicines in Q2 2024 and held it in 5 quarters.
Advisors Asset Management's Blueprint Medicines position peaked at $699K in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Advisors Asset Management's 13F filing for Q3 2025, filed 6 Nov 2025.